Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

INS018_055

"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"

DRUG

Placebo

"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"

Trial Locations (22)

100041

Peking University Shougang Hospital, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

110004

The Shengjing Hospital of China medical university, Shenyang

200030

Shanghai Chest Hospital, Shanghai

200032

Zhongshan hospital Fudan University, Shanghai

201800

Shanghai Pulmonary Hospital, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

230031

Anhui Chest Hospital, Hefei

230601

The Second Affiliated Hospital of Anhui Medical University, Hefei

250013

Qilu Hospital of Shandong University, Jinan

300052

General Hospital of Tianjin Medical University, Tianjin

310006

The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou

330006

Jiangxi Provincial People's Hospital, Nanchang

410008

Xiangya Hospital of Central South University, Changsha

410011

The Second Xiangya Hospital of Central South University, Changsha

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

570311

Hainan General Hoapital, Haikou

610041

The West China Hospital of Sichuan University, Chengdu

030032

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY

NCT05938920 - Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter